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Background and Methods: Steroid-refractory acute GVHD (SR-
GVHD) remains a significant complication of allogeneic hematopoi-
etic cell transplantation (HCT). Prochymal (Mesenchymal Stem
Cells, MSC, derived from unrelated volunteer adult donors) was
evaluated in addition to standard of care, including institutionally se-
lected second line treatment, in a randomized (2:1) trial in patients
with SR-GVHD (Protocol 280). Patients received 8 infusions of 2
 106 MSC/kg over 4 weeks (or volume equivalent for placebo),
with an additional 4 infusions administered weekly after day 28 in pa-
tients who had a partial response, defined as improvement in at least
one organ without progression in others. The primary endpoint was
durable complete response (DCR) for$ 28 days. Additional pro-
spectively defined outcomes included responses in patients by organ
involvement. P-values were based on Chi-square tests, unless other-
wise specified.
Patients and Results: 244 patients with SR-GVHD (skin involve-
ment n5 144, GI involvement n5 179, liver involvement n5 61)
were enrolled and treated on study: Prochymal (n5 163), placebo
(n5 81). There were no significant differences in age, pre-trans-
plant conditioning, graft source, HLA-matching or second-line
therapy between treatment arms. For the Prochymal and placebo
arms, respectively, the grades of GVHD at entry were B (22%
vs. 26%), C (51% vs. 58%), and D (27% vs. 16%). The respective
DCR rates were 35% vs. 30% (p5 0.3) in the ITT population and
40% vs. 28% (p5 0.08) in the per protocol population. Results for
secondary endpoints are shown in the table. Patients with GvHD
affecting all 3 organs had overall complete or partial responses
rate of 63% vs. 0% (n5 22, p\0.05, Fisher’s exact test) at day
28. Patients treated with Prochymal had less progression of liver
GVHD at weeks 2 and 4 respectively (32% vs 59%, p5 0.05;
and 37% vs. 65%, p5 0.05). The incidence of infections was not
different between arms. Incidence rates were 9% vs. 8% for recur-
rent malignancy, 1.8% vs. 2.5% for infusional toxicity, and 0.6%
vs. 4.6% for discontinuation due to an AE in Prochymal versus
Placebo, respectively.
Conclusion:GVHDwith liver or gut involvement is a life-threaten-
ing complication of HCT. Our results suggest that the addition of
Prochymal produced significant improvement without additive tox-
icity in patients with SR-GVHD involving visceral organs.
Overall Complete or Partial Response Rates in Patients
According to Organ Involvement
Day 100 Response RateOrgan Prochymal Placebo Odds Ratio 95% CI P ValueOverall 82% 73% 1.7 0.9-3.1 0.12
Skin 78% 77% 1.1 0.5-2.4 0.9
Liver 76% 47% 3.6 1.1-11.2 \0.05
Gut 82% 68% 2.2 1.1-4.4 \0.0542
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The current paradigm indicates that epitope speading is critical
for GVHD after MHCmatched minor antigen (miHA) mismatched
BMT. Because clinical data suggest that sex mismatched antigens are
relevant miHAs for GVH responses, we directly tested relevance of
epitope spreading by inducingGVHDin the presence of only a single
immuno-dominant Y antigen disparity. We utilized female (F)/
male(M) MHC matched BMT with anti-H-Y monospecific,
H-2(b)-restricted T cell receptor transgenic (TCR Tg) MataHariCD8+ T cells. B6 [M and F] animals were lethally irradiated and
transplanted with TCD BM and 1106 splenic CD8+ T cells from
\MataHari donors. None of the syngeneic female B6 animals devel-
oped GVHD and all of them survived. By contrast, all of the alloge-
neic male animals that received MataHari T cells showed severe
clinical GVHD and died after BMT (P\0.0001, see Table).
GVHD specific death was confirmed by target organ (GI tract and
liver) histopathology on day +7 after BMT (P\0.005). To deter-
mine if the precursor frequency alloreactive donor T cells is critical,
we reduced the dose of the MataHari T cells by ten fold (1105) and
mixed them with syngeneic T cells (1:9 ratio) from male B6 donors.
Significant GVHD mortality was observed in the MataHari group
(33% vs. 0%, P\0.01) demonstrating that the presence of sufficient
precursor T cells against a single immuno-dominat miHA can
induce significant GVHD even in the absence of epitope spreading.
GVHD mortality was also observed when two other anti-H-Y spe-
cific TCR Tg CD4+ (Marilyn and Rachel) were utilized as donor
T cells ruling out any CD8+ T cell only or strain dependent artifacts.
Mechanistic studies were performed to determine whether direct
and/or cross-presentation (on host or donor hematopoietic derived
APCs) of the immunodominant miHA is critical for GVHD.
[F/M], [II-/-/M] and [M/ F] bone marrow chimeras gener-
ated, lethally re-irradiated and injected with TCD-BM and Marilyn
CD4+ T cells. The [F/M], [II-/-/M] animals (express HY anti-
gen on only non-hematopoietic target cells) died from severe
GVHD while the [M/ F] animals (express HY antigen on only
hematopoietic cells) showed only modest GVHD. Collectively our
data (see Table) demonstrate that (a) in contrast to the current
dogma, epitope spreading is not always required for GVHD (b)
the immunodominant antigen expression on target tissues is critical
and (c) this antigen can be efficiently cross-presented by either host
or donor APCs.
GVHD across single immuno-dominant Yantigen miHA
GVHD mortality
Donor T cells (all of B6\ TCDBM) Recipient * P\0.01MataHari (CD81 Tg, 1x106) B6 (female) 0%
MataHari (CD81 Tg, 1x106) B6 (male) 100%
MataHari (CD81 Tg, 0.1x106) B6 (male) 33%
Marilyn (CD41 Tg, 1x106) B6 (male) 100%
Rachel (CD41 Tg, 1x106) B6 (male) 100%
Marilyn (CD41 Tg, 1x106) [B6\ into B6_ 100%
Marilyn (CD41 Tg, 1x106) [B6(male) into B6\ 25%
Marilyn (CD41 Tg, 1x106) [II-/- into B6_ 100%43
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Allogeneic hematopoietic stem cell transplantation (allo-HSCT)
is a curative treatment for many hematologic malignancies or hema-
topoietic dysfunction syndromes in adult patients, but the applica-
tion is still limited due to major complications, such as severe graft
versus host disease (GvHD) and/or infectious complications. Diag-
nosis of aGvHD is based on clinical features and biopsies, a non
invasive, unbiased laboratory test was developed earlier and has
been evaluated prospectively and blinded onmore than 1290 samples
collected from more than 327 patients undergoing allo-HSCT at
Hannover Medical School (MHH) and 7 additional clinics. The
majority of the patients included was transplanted for hematological
malignancies (n5 320), 9 for hematopoietic failure syndromes,
